UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper T
Go back to UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper T(NASDAQ: URGN) | Delayed: 15.00 +0.04 (0.27%) | |||||
---|---|---|---|---|---|---|
Previous Close | $14.96 | 52 Week High | $ | |||
Open | $14.92 | 52 Week Low | $ | |||
Day High | $15.25 | P/E | N/A | |||
Day Low | $14.56 | EPS | $ | |||
Volume | 200,826 |